PL2601214T3 - Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania - Google Patents

Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania

Info

Publication number
PL2601214T3
PL2601214T3 PL11745870T PL11745870T PL2601214T3 PL 2601214 T3 PL2601214 T3 PL 2601214T3 PL 11745870 T PL11745870 T PL 11745870T PL 11745870 T PL11745870 T PL 11745870T PL 2601214 T3 PL2601214 T3 PL 2601214T3
Authority
PL
Poland
Prior art keywords
vegf antagonist
antagonist compositions
compositions
vegf
antagonist
Prior art date
Application number
PL11745870T
Other languages
English (en)
Inventor
James Stefano
Clark Pan
Huawei Qiu
Michael O'callaghan
Gloria Matthews
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL2601214T3 publication Critical patent/PL2601214T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11745870T 2010-08-06 2011-08-05 Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania PL2601214T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37154610P 2010-08-06 2010-08-06
EP11745870.3A EP2601214B1 (en) 2010-08-06 2011-08-05 Vegf antagonist compositions and uses thereof
PCT/US2011/046802 WO2012019128A1 (en) 2010-08-06 2011-08-05 Vegf antagonist compositions and uses thereof

Publications (1)

Publication Number Publication Date
PL2601214T3 true PL2601214T3 (pl) 2018-05-30

Family

ID=44630479

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11745870T PL2601214T3 (pl) 2010-08-06 2011-08-05 Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania

Country Status (12)

Country Link
US (2) US9441029B2 (pl)
EP (2) EP3327032A1 (pl)
CY (1) CY1121111T1 (pl)
DK (1) DK2601214T3 (pl)
ES (1) ES2652508T3 (pl)
HR (1) HRP20180154T1 (pl)
HU (1) HUE035554T2 (pl)
LT (1) LT2601214T (pl)
PL (1) PL2601214T3 (pl)
PT (1) PT2601214T (pl)
SI (1) SI2601214T1 (pl)
WO (1) WO2012019128A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3377101A4 (en) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. VEGF BINDING METHODS AND COMPOSITIONS
AU2019212622B2 (en) 2018-01-26 2024-05-23 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
ATE140963T1 (de) 1988-01-22 1996-08-15 Zymogenetics Inc Verfahren zur herstellung von sekretierten rezeptoranalogen
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
JPH03233530A (ja) 1990-02-09 1991-10-17 Fuji Photo Optical Co Ltd カメラ
US20020032313A1 (en) 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
ES2360641T3 (es) 1992-10-28 2011-06-07 Genentech, Inc. Uso de antagonistas del factor de crecimiento endotelial vascular.
FR2702152B1 (fr) 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
AU684498B2 (en) 1993-03-25 1997-12-18 Merck & Co., Inc. Inhibitor of vascular endothelial cell growth factor
US6686200B1 (en) 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP2001501471A (ja) 1996-09-24 2001-02-06 メルク エンド カンパニー インコーポレーテッド 血管新生の阻害のための遺伝子治療
JP3837748B2 (ja) 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
AU7383298A (en) 1997-05-13 1998-12-08 Regents Of The University Of California, The Novel antiangiogenic peptide agents and their therapeutic and diagnostic use
JP2002511750A (ja) 1997-06-03 2002-04-16 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ ｉｎ ｖｉｖｏにおいて内皮細胞に異種ＤＮＡ配列を発現させる能力のある制御配列とその使用法
ES2292204T3 (es) 1997-06-18 2008-03-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Receptor de tipo tirosina cinasa humano, kdr.
WO1999014354A1 (en) 1997-09-19 1999-03-25 The Trustees Of The University Of The Pennsylvania Methods and vector constructs useful for production of recombinant aav
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
JP2002539176A (ja) 1999-03-15 2002-11-19 カイロン コーポレイション 眼の疾患を処置または予防するための組換え遺伝子送達ベクターの使用
CZ303656B6 (cs) 1999-06-08 2013-01-30 Regeneron Pharmaceuticals, Inc. Lécivo pro lécení ocního onemocnení
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
WO2002024234A2 (en) 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
RU2292904C2 (ru) 2001-01-09 2007-02-10 Мерк Патент Гмбх Комбинированная терапия, использующая ингибиторы рецептора тирозинкиназы и ингибиторы ангиогенезиса
NZ535100A (en) 2002-03-20 2008-04-30 Univ Florida RAAV vector compositions and methods for the treatment of choroidal neovascularization
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
CA2520254A1 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
ATE470454T1 (de) * 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
CA2587932A1 (en) 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers

Also Published As

Publication number Publication date
US20130324465A1 (en) 2013-12-05
ES2652508T3 (es) 2018-02-02
EP2601214B1 (en) 2017-11-01
HRP20180154T1 (hr) 2018-03-09
DK2601214T3 (en) 2018-02-05
WO2012019128A1 (en) 2012-02-09
US9441029B2 (en) 2016-09-13
HUE035554T2 (en) 2018-05-02
US20160326501A1 (en) 2016-11-10
CY1121111T1 (el) 2019-12-11
US10308917B2 (en) 2019-06-04
SI2601214T1 (en) 2018-03-30
EP2601214A1 (en) 2013-06-12
PT2601214T (pt) 2017-12-20
LT2601214T (lt) 2018-02-26
EP3327032A1 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
ZA201209259B (en) Uses and compositions
IL225463A0 (en) Preparations containing a tlr agonist and uses thereof
GB201002983D0 (en) Nutritinal composition
GB201006200D0 (en) Composition
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
GB201006096D0 (en) Novel compositions and uses thereof
EP2629742A4 (en) HAIR CARE COMPOSITIONS AND RELATED METHODS
EP2522643A4 (en) CONCRETE COMPOSITION
GB201113770D0 (en) Novel compositions and uses thereof
GB201006178D0 (en) Composition
GB2482365B (en) Toner compositions and processes
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
IL219987A0 (en) Dp2 antagonist and uses thereof
HK1201451A1 (en) Compositions and methods
GB2483947B (en) Toner compositions and processes
GB201018650D0 (en) Methods and compositions
ZA201206579B (en) Endoparasiticidal compositions
PT2601214T (pt) Composições de antagonistas de vegf e utilizações destes
EP2776064A4 (en) ANTAGONISTS OF PRO-VASOPRESSIN AND USES THEREOF
GB2478399B (en) Toner compositions and methods
GB201012848D0 (en) Cement-containing compositions
GB201006204D0 (en) Composition
GB201004717D0 (en) Composition
GB201006175D0 (en) Composition
GB201005826D0 (en) New compositions and their use